IOmet Pharma Ltd.
Patent Applications and Registrations
Patent applications and USPTO patent grants for IOmet Pharma Ltd..The latest application filed is for "novel substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase".
- IOmet Pharma Ltd. - Edinburgh GB
- IOMet Pharma Ltd. - Midlothian GB
- IOMet Pharma Ltd. - Edinburgh, Scotland NJ
- IOmet Pharma Ltd. - Edinburgh, Midlothian N/A GB
- Iomet Pharma Ltd. - GB GB
- IOmet Pharma Ltd. - Edinburgh, Midothian, Scotland GB
- IOmet Pharma ltd. - Midlothian, Scotland GB
- IOmet Pharma Ltd. - Rahway NJ
- IOMET PHARMA LTD - Edinburgh, Midlothian GB
| Patent | Date |
|---|---|
| Pharmaceutical compound Grant 11,130,738 - Cowley , et al. September 28, 2 | 2021-09-28 |
| Substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase Grant 11,096,930 - Cowley , et al. August 24, 2 | 2021-08-24 |
| Indole derivatives for use in medicine Grant 10,858,319 - Cowley , et al. December 8, 2 | 2020-12-08 |
| Novel Substituted Imidazopyridine Compounds As Inhibitors Of Indoleamine 2,3-dioxygenase And/or Tryptophan-2,3-dioxygenase App 20200230117 - Cowley; Phillip M. ; et al. | 2020-07-23 |
| Pharmaceutical Compound App 20200172492 - Cowley; Phillip M. ; et al. | 2020-06-04 |
| Pharmaceutical compound Grant 10,590,086 - Cowley , et al. | 2020-03-17 |
| Substituted bicyclic fused ring compounds as indoleamine-2,3-dioxygenase inhibitors Grant 10,501,458 - Cowley , et al. Dec | 2019-12-10 |
| Substituted 1H-indole-2-carboxamide compounds as indoleamine-2,3-dioxygenase inhibitors Grant 10,336,731 - Cowley , et al. | 2019-07-02 |
| Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase Grant 10,287,252 - Cowley , et al. | 2019-05-14 |
| Indole Derivatives For Use In Medicine App 20190084933 - Cowley; Phillip M. ; et al. | 2019-03-21 |
| Indole derivatives for use in medicine Grant 10,167,257 - Cowley , et al. J | 2019-01-01 |
| Screening method Grant 10,155,972 - Hunter , et al. Dec | 2018-12-18 |
| Pharmaceutical Compound App 20180354908 - Cowley; Phillip M. ; et al. | 2018-12-13 |
| Pharmaceutical Compound App 20180258075 - Cowley; Phillip M. ; et al. | 2018-09-13 |
| Pharmaceutical compound Grant 10,047,074 - Cowley , et al. August 14, 2 | 2018-08-14 |
| Pharmaceutical Compound App 20180186787 - Cowley; Phillip M. ; et al. | 2018-07-05 |
| Pharmaceutical compound Grant 9,931,347 - Cowley , et al. April 3, 2 | 2018-04-03 |
| Inhibitors Of Tryptophan-2,3-dioxygenase Or Indoleamine-2,3-dioxygenase App 20180037553 - Cowley; Phillip M. ; et al. | 2018-02-08 |
| Pharmaceutical Compound App 20170267668 - COWLEY; Phillip M. ; et al. | 2017-09-21 |
| Indole Derivatives For Use In Medicine App 20170107178 - COWLEY; Phillip M. ; et al. | 2017-04-20 |
| Screening Method App 20170009271 - Hunter; Bill ; et al. | 2017-01-12 |
| Pharmaceutical Compound App 20160367564 - Cowley; Phillip Martin ; et al. | 2016-12-22 |
| Slc2a Transporter Inhibitors App 20160120863 - Cowley; Phillip Martin ; et al. | 2016-05-05 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 